China De Xiao Quan Care Group Co., Ltd

2023 Q2 Form 10-Q Financial Statement

#000168316823005929 Filed on August 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q2

Balance Sheet

Concept 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $0.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $0.00
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $0.00
Total Long-Term Assets $0.00
Total Assets $0.00
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $489.0K
YoY Change 0.0%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $960.2K
YoY Change -70.07%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $960.2K
Total Long-Term Liabilities
Total Liabilities $960.2K
YoY Change -70.07%
SHAREHOLDERS EQUITY
Retained Earnings -$1.163M
YoY Change -65.89%
Common Stock $3.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$960.2K
YoY Change
Total Liabilities & Shareholders Equity $0.00
YoY Change

Cashflow Statement

Concept 2023 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001552979
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-182761
dei Entity Registrant Name
EntityRegistrantName
CHINA DE XIAO QUAN CARE GROUP CO., LTD.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
38-3870905
dei Entity Address Address Line1
EntityAddressAddressLine1
Room 515, Block A
dei Entity Address Address Line2
EntityAddressAddressLine2
No. 9 Huida Road
dei Entity Address Address Line3
EntityAddressAddressLine3
Jiangbei New District
dei Entity Address City Or Town
EntityAddressCityOrTown
Nanjing
dei Entity Address Country
EntityAddressCountry
CN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
210031
dei City Area Code
CityAreaCode
86
dei Local Phone Number
LocalPhoneNumber
18118841599
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30000000 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
0 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
0 usd
CY2023Q2 us-gaap Assets
Assets
0 usd
CY2022Q4 us-gaap Assets
Assets
0 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
770236 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1340344 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
190000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
590000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
960236 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1930344 usd
CY2023Q2 us-gaap Liabilities
Liabilities
960236 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1930344 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30000000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30000000 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
500000 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
50 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
50 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
200200 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
200200 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1163486 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2133594 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-960236 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1930344 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
14909 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
70238 usd
us-gaap Interest Expense
InterestExpense
51522 usd
us-gaap Interest Expense
InterestExpense
140475 usd
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1021630 usd
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1021630 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1006721 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-70238 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
970108 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-140475 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
1006721 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-70238 usd
us-gaap Net Income Loss
NetIncomeLoss
970108 usd
us-gaap Net Income Loss
NetIncomeLoss
-140475 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30000000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30000000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
530000000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
530000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30000000 shares
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-3137839 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-70238 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-3208077 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1966957 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
1006721 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-960236 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-3067602 usd
us-gaap Net Income Loss
NetIncomeLoss
-140475 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-3208077 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1930344 usd
us-gaap Net Income Loss
NetIncomeLoss
970108 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-960236 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
970108 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-140475 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1021630 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-0 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
51522 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
140475 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
CDXQ Principal Payments On Notes Payable
PrincipalPaymentsOnNotesPayable
0 usd
CDXQ Principal Payments On Notes Payable
PrincipalPaymentsOnNotesPayable
0 usd
CDXQ Issued Preferred Stock
IssuedPreferredStock
0 usd
CDXQ Issued Preferred Stock
IssuedPreferredStock
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
285000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_843_eus-gaap--UseOfEstimates_zj8Zs98k0Qa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86F_zUqG5L9n3wxl">Use of estimates</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the estimated useful lives of property and equipment. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><i> </i></p>
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500000000 shares
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1163486 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
489044 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
489044 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
281192 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
851300 usd
CY2023Q2 CDXQ Accounts Payable And Accrued Liabilities Current1
AccountsPayableAndAccruedLiabilitiesCurrent1
770236 usd
CY2022Q4 CDXQ Accounts Payable And Accrued Liabilities Current1
AccountsPayableAndAccruedLiabilitiesCurrent1
1340344 usd
CY2023Q2 us-gaap Debt Default Longterm Debt Amount
DebtDefaultLongtermDebtAmount
1190000 usd
CY2022Q4 us-gaap Debt Default Longterm Debt Amount
DebtDefaultLongtermDebtAmount
1190000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1021630 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1418208 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
190000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
590000 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
281192 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
851300 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
51522 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
140475 usd
CY2023Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
244000 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
448000 usd

Files In Submission

Name View Source Status
cdxq-20230630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001683168-23-005929-index-headers.html Edgar Link pending
0001683168-23-005929-index.html Edgar Link pending
0001683168-23-005929.txt Edgar Link pending
0001683168-23-005929-xbrl.zip Edgar Link pending
cdxq-20230630.xsd Edgar Link pending
cdxq_ex3101.htm Edgar Link pending
cdxq_ex3102.htm Edgar Link pending
cdxq_ex3201.htm Edgar Link pending
cdxq_ex3202.htm Edgar Link pending
cdxq_i10q-063023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
cdxq-20230630_pre.xml Edgar Link unprocessable
cdxq-20230630_lab.xml Edgar Link unprocessable
cdxq_i10q-063023_htm.xml Edgar Link completed
report.css Edgar Link pending
Show.js Edgar Link pending
cdxq-20230630_cal.xml Edgar Link unprocessable